Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15778420,association constants,"The association constants for alpha-1 acid glycoprotein and human plasma were approximately 8 x 10(8)(mol/L)(-1), indicating extremely high affinity.",Review of UCN-01 development: a lesson in the importance of clinical pharmacology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778420/),[mol] / [l],8 x 10(8),4654,DB02010,Staurosporine
over,7663699,recoveries,The sample pretreatment involves liquid-liquid extraction with diisopropyl ether with recoveries over 88%.,Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7663699/),%,88,10326,DB02010,Staurosporine
,7663699,limit of detection,"The limit of detection and limit of quantitation of the parent compound and two metabolites were 0.5 and 1.0 ng/ml, respectively.",Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7663699/),[ng] / [ml],0.5,10327,DB02010,Staurosporine
,7663699,limit of quantitation,"The limit of detection and limit of quantitation of the parent compound and two metabolites were 0.5 and 1.0 ng/ml, respectively.",Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7663699/),[ng] / [ml],1.0,10328,DB02010,Staurosporine
,7663699,limit of detection,"For the third metabolite the limit of detection and limit of quantitation were 1.0 and 2.0 ng/ml, respectively.",Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7663699/),[ng] / [ml],1.0,10329,DB02010,Staurosporine
,7663699,limit of quantitation,"For the third metabolite the limit of detection and limit of quantitation were 1.0 and 2.0 ng/ml, respectively.",Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7663699/),[ng] / [ml],2.0,10330,DB02010,Staurosporine
,11230495,elimination half-life,"The estimated median elimination half-life was 1.6 days (range, 0.9 to 4.0 days), and a metabolite with a median half-life of 36 days was detected.","Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230495/),d,1.6,14221,DB02010,Staurosporine
,11230495,half-life,"The estimated median elimination half-life was 1.6 days (range, 0.9 to 4.0 days), and a metabolite with a median half-life of 36 days was detected.","Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230495/),d,36,14222,DB02010,Staurosporine
,11230495,50% inhibitory concentration,Steady-state PKC412 plasma levels at the top three dose cohorts (150 to 300 mg) were five to 10 times the cellular 50% inhibitory concentration for PKC412 of 0.2 to 0.7 micromol/L.,"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11230495/),[μM] / [l],0.2 to 0.7,14223,DB02010,Staurosporine
,28270565,plasma half-lives,"Long plasma half-lives were observed for midostaurin (20.3 hours), CGP52421 (495 hours), and CGP62221 (33.4 hours).","Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270565/),h,20.3,63441,DB02010,Staurosporine
,28270565,plasma half-lives,"Long plasma half-lives were observed for midostaurin (20.3 hours), CGP52421 (495 hours), and CGP62221 (33.4 hours).","Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270565/),h,495,63442,DB02010,Staurosporine
,28270565,plasma half-lives,"Long plasma half-lives were observed for midostaurin (20.3 hours), CGP52421 (495 hours), and CGP62221 (33.4 hours).","Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270565/),h,33.4,63443,DB02010,Staurosporine
,28270565,Renal elimination,Renal elimination was minor (4%).,"Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270565/),%,4,63444,DB02010,Staurosporine
>,28270565,plasma protein binding,Very high plasma protein binding (>99%) required equilibrium gel filtration to identify differences between humans and animals.,"Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270565/),%,99,63445,DB02010,Staurosporine
,10070963,hepatic extraction ratio,"Furthermore, human AGP markedly reduced the hepatic extraction ratio of UCN-01 from 0.510 to 0.0326.","Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070963/),,0.510,69093,DB02010,Staurosporine
,10070963,hepatic extraction ratio,"Furthermore, human AGP markedly reduced the hepatic extraction ratio of UCN-01 from 0.510 to 0.0326.","Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070963/),,0.0326,69094,DB02010,Staurosporine
,19026036,CL(1),"In the pre-induced state, CL(1) and CL(2) of midostaurin were determined to be 1.47 L/h and 0.501 L/h, respectively.",A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026036/),[l] / [h],1.47,71148,DB02010,Staurosporine
,19026036,CL(2),"In the pre-induced state, CL(1) and CL(2) of midostaurin were determined to be 1.47 L/h and 0.501 L/h, respectively.",A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026036/),[l] / [h],0.501,71149,DB02010,Staurosporine
,19026036,maximum fold of induction (E(max)),The final model estimated a mean maximum fold of induction (E(max)) of 8.61 and a concentration producing 50% of the E(max) (EC(50)) of 1700 ng/mL (approximately 2.9 micromol/L) for CGP52421-mediated enzyme induction.,A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026036/),,8.61,71150,DB02010,Staurosporine
,19026036,E(max) (EC(50)),The final model estimated a mean maximum fold of induction (E(max)) of 8.61 and a concentration producing 50% of the E(max) (EC(50)) of 1700 ng/mL (approximately 2.9 micromol/L) for CGP52421-mediated enzyme induction.,A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026036/),[ng] / [ml],1700,71151,DB02010,Staurosporine
,19026036,E(max) (EC(50)),The final model estimated a mean maximum fold of induction (E(max)) of 8.61 and a concentration producing 50% of the E(max) (EC(50)) of 1700 ng/mL (approximately 2.9 micromol/L) for CGP52421-mediated enzyme induction.,A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026036/),[μM] / [l],2.9,71152,DB02010,Staurosporine
,16284058,half-life,Pharmacokinetic analysis confirmed the prolonged half-life of UCN-01 of approximately 15 days.,Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284058/),d,15,85490,DB02010,Staurosporine
,15699481,maximal plasma concentration,The mean maximal plasma concentration of UCN-01 was 33.5 micromol/L.,Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15699481/),[μM] / [l],33.5,89229,DB02010,Staurosporine
,7987983,maximum tolerated doses (MTD),"For mice dosed intravenously, subcutaneously, or by oral gavage with this compound, the maximum tolerated doses (MTD) were 20, 10, and > 100 mg/kg, respectively.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),[mg] / [kg],20,97156,DB02010,Staurosporine
,7987983,maximum tolerated doses (MTD),"For mice dosed intravenously, subcutaneously, or by oral gavage with this compound, the maximum tolerated doses (MTD) were 20, 10, and > 100 mg/kg, respectively.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),[mg] / [kg],10,97157,DB02010,Staurosporine
,7987983,half-lives,"Following an intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 alpha) and terminal (t1/2 beta) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,10,97158,DB02010,Staurosporine
,7987983,half-lives,"Following an intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 alpha) and terminal (t1/2 beta) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,85,97159,DB02010,Staurosporine
,7987983,t1/2 alpha,"Following an intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 alpha) and terminal (t1/2 beta) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,10,97160,DB02010,Staurosporine
,7987983,t1/2 alpha,"Following an intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 alpha) and terminal (t1/2 beta) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,85,97161,DB02010,Staurosporine
,7987983,area under the plasma concentration-time curve (AUC value),"Following an intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 alpha) and terminal (t1/2 beta) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),[min·μg] / [ml],117,97162,DB02010,Staurosporine
,7987983,half-life of the elimination phase,"In mice dosed by oral gavage with 10 mg/kg, the calculated value for the half-life of the elimination phase was 150 min.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,150,97163,DB02010,Staurosporine
,7987983,AUC,"The AUC value was 15 micrograms min ml-1, giving a value for bioavailability of 13%.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),[min·μg] / [ml],15,97164,DB02010,Staurosporine
,7987983,bioavailability,"The AUC value was 15 micrograms min ml-1, giving a value for bioavailability of 13%.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),%,13,97165,DB02010,Staurosporine
,7987983,half-lives,"After subcutaneous dosing with 10 mg/kg, the calculated values for half-lives for the distribution and elimination phases were 23 and 130 min, respectively; the AUC value was 113 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,23,97166,DB02010,Staurosporine
,7987983,half-lives,"After subcutaneous dosing with 10 mg/kg, the calculated values for half-lives for the distribution and elimination phases were 23 and 130 min, respectively; the AUC value was 113 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),min,130,97167,DB02010,Staurosporine
,7987983,AUC,"After subcutaneous dosing with 10 mg/kg, the calculated values for half-lives for the distribution and elimination phases were 23 and 130 min, respectively; the AUC value was 113 micrograms min ml-1.","Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987983/),[min·μg] / [ml],113,97168,DB02010,Staurosporine
,11269735,terminal half-lives,"The radioactivity in rat and dog plasma disappeared triphasically with terminal half-lives of 21.3 and 27.2 h, respectively.","Pharmacokinetics, distribution, metabolism and excretion of. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269735/),h,21.3,124863,DB02010,Staurosporine
,11269735,terminal half-lives,"The radioactivity in rat and dog plasma disappeared triphasically with terminal half-lives of 21.3 and 27.2 h, respectively.","Pharmacokinetics, distribution, metabolism and excretion of. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269735/),h,27.2,124864,DB02010,Staurosporine
,29117990,area under the curve ratio,The simulated midazolam area under the curve ratio of 0.54 and an accompanying observed 1.9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM.,Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117990/),,0.54,137187,DB02010,Staurosporine
,17429623,half-life,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),h,292.0,138759,DB02010,Staurosporine
,17429623,clearance,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),[l] / [h],0.045,138760,DB02010,Staurosporine
,17429623,volume of distribution,"The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data.",Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429623/),l,14.3,138761,DB02010,Staurosporine
,9699650,distribution volumes,"The distribution volumes (0.0796-0.158 liters/kg) and the systemic clearance (0.0407-0.252 ml/h/kg) were extremely low, in contrast to large distribution volume and rapid systemic clearance in experimental animals.",Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699650/),[l] / [kg],0.0796-0.158,142438,DB02010,Staurosporine
,9699650,systemic clearance,"The distribution volumes (0.0796-0.158 liters/kg) and the systemic clearance (0.0407-0.252 ml/h/kg) were extremely low, in contrast to large distribution volume and rapid systemic clearance in experimental animals.",Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699650/),[ml] / [h·kg],0.0407-0.252,142439,DB02010,Staurosporine
,9699650,elimination half-lives,The elimination half-lives (253-1660 h) were unusually long.,Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699650/),h,253-1660,142440,DB02010,Staurosporine
,18508951,accumulation factor (R),"Midostaurin concentrations increased during the first 3 to 6 days of dosing, then declined with time (by 30%-50%) until a steady state was achieved, representing an average accumulation factor (R) of 1.7.",Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508951/),,1.7,156290,DB02010,Staurosporine
,17145831,half-life (T(1/2)),Median plasma UCN-01 half-life (T(1/2)) was 405 hours.,Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145831/),h,405,161258,DB02010,Staurosporine
,17145831,T(1/2alpha),"Salivary UCN-01 concentrations showed a rapid initial decline (median T(1/2alpha), 29.9 hours), followed by a terminal decay parallel to that in plasma.",Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145831/),h,29.9,161259,DB02010,Staurosporine
,10888307,Vdss,"The Vdss and CLtot following 72.5-7250 nmol/kg UCN-01 to rats given 150 nmol/h/kg hAGP were 63.9-688 ml/kg and 3.18-32.9 ml/h/kg, respectively, indicating non-linearity due to saturation of UCN-01 binding.","Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10888307/),[ml] / [kg],63.9-688,188965,DB02010,Staurosporine
,10888307,CLtot,"The Vdss and CLtot following 72.5-7250 nmol/kg UCN-01 to rats given 150 nmol/h/kg hAGP were 63.9-688 ml/kg and 3.18-32.9 ml/h/kg, respectively, indicating non-linearity due to saturation of UCN-01 binding.","Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10888307/),[ml] / [h·kg],3.18-32.9,188966,DB02010,Staurosporine
,11304786,total plasma concentration,"Pharmacokinetic determinations at the recommended dose of 42.5 mg/m(2)/d for 3 days included mean total plasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h.",Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304786/),μM,36.4,192108,DB02010,Staurosporine
,11304786,terminal elimination half-life,"Pharmacokinetic determinations at the recommended dose of 42.5 mg/m(2)/d for 3 days included mean total plasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h.",Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304786/),h,447 to 1176,192109,DB02010,Staurosporine
,11304786,steady-state volume of distribution,"Pharmacokinetic determinations at the recommended dose of 42.5 mg/m(2)/d for 3 days included mean total plasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h.",Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304786/),l,9.3 to 14.2,192110,DB02010,Staurosporine
,11304786,clearances,"Pharmacokinetic determinations at the recommended dose of 42.5 mg/m(2)/d for 3 days included mean total plasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h.",Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304786/),[l] / [h],0.005 to 0.033,192111,DB02010,Staurosporine
,11304786,total salivary concentration,The mean total salivary concentration was 111 nmol/L of UCN-01.,Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304786/),[nM] / [l],111,192112,DB02010,Staurosporine
,17473198,area under the curve (AUC),Carboplatin was escalated from an area under the curve (AUC) of 3 to an AUC of 5.,Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17473198/),,3,194736,DB02010,Staurosporine
,17473198,AUC,Carboplatin was escalated from an area under the curve (AUC) of 3 to an AUC of 5.,Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17473198/),,5,194737,DB02010,Staurosporine
,17473198,t(1/2),"The average t(1/2) for cycle 1 was 506 +/- 301 h, and the mean C(max) for all dose levels was >30 micromol/L.",Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17473198/),h,506,194738,DB02010,Staurosporine
>,17473198,C(max),"The average t(1/2) for cycle 1 was 506 +/- 301 h, and the mean C(max) for all dose levels was >30 micromol/L.",Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17473198/),[μM] / [l],30,194739,DB02010,Staurosporine
,17473198,AUC,"The mean AUC over the dosing interval for each dose level ranged from approximately 6,000 to 9,000 micromol/L h.",Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17473198/),[μM] / [h·l],"6,000 to 9,000",194740,DB02010,Staurosporine
,23443507,MTD,The MTD was determined to be UCN-01 65 mg/m(2) with perifosine 100 mg a day.,Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23443507/),[mg] / [m],65,205505,DB02010,Staurosporine
,15501960,total drug clearance,"Over the tested dose range, total drug clearance was distinctly nonlinear (P = 0.0076) and increased exponentially from 4.33 mL/hour (at 3.6 mg/m(2)/day) to 24.1 mL/hour (at 54 mg/m(2)/day).",Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501960/),[ml] / [h],4.33,206293,DB02010,Staurosporine
,15501960,total drug clearance,"Over the tested dose range, total drug clearance was distinctly nonlinear (P = 0.0076) and increased exponentially from 4.33 mL/hour (at 3.6 mg/m(2)/day) to 24.1 mL/hour (at 54 mg/m(2)/day).",Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501960/),[ml] / [h],24.1,206294,DB02010,Staurosporine
,11911284,distribution half-life,"The distribution half-life was 0.2 hours, while the elimination half-life was 6.65 hours.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),h,0.2,218241,DB02010,Staurosporine
,11911284,elimination half-life,"The distribution half-life was 0.2 hours, while the elimination half-life was 6.65 hours.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),h,6.65,218242,DB02010,Staurosporine
,11911284,volume of distribution of the central compartment (Vc),The volume of distribution of the central compartment (Vc) was 1000 ml/kg and the volume of distribution during the elimination phase (Vdb) was 2551 ml/kg.,Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg],1000,218243,DB02010,Staurosporine
,11911284,volume of distribution during the elimination phase (Vdb),The volume of distribution of the central compartment (Vc) was 1000 ml/kg and the volume of distribution during the elimination phase (Vdb) was 2551 ml/kg.,Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg],2551,218244,DB02010,Staurosporine
,11911284,total body clearance (TBC),The total body clearance (TBC) was 4.4 ml/min/kg.,Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg·min],4.4,218245,DB02010,Staurosporine
,11911284,Vc,"Furthermore, the Vc, Vd(beta) and TBC were significantly reduced to 395 ml/kg, 735 ml/kg and 1.34 ml/min/kg, respectively.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg],395,218246,DB02010,Staurosporine
,11911284,Vd(beta),"Furthermore, the Vc, Vd(beta) and TBC were significantly reduced to 395 ml/kg, 735 ml/kg and 1.34 ml/min/kg, respectively.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg],735,218247,DB02010,Staurosporine
,11911284,TBC,"Furthermore, the Vc, Vd(beta) and TBC were significantly reduced to 395 ml/kg, 735 ml/kg and 1.34 ml/min/kg, respectively.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),[ml] / [kg·min],1.34,218248,DB02010,Staurosporine
>,11911284,tissue to plasma ratio,"The presence of hAGP drastically reduced tissue accumulation of UCN-01, although the tissue to plasma ratio remained > 1.0 except for the brain.",Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11911284/),,1.0,218249,DB02010,Staurosporine
,23242585,overall response (complete response (CR) + partial response (PR)) rate,The overall response (complete response (CR) + partial response (PR)) rate was 4 %.,A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),%,4,227378,DB02010,Staurosporine
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,5.5,227379,DB02010,Staurosporine
,23242585,overall survival,"Median overall survival in patients with TP53 mutant tumors was poor compared to wild type (5.5 vs. 20.3 months, p = 0.004).",A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242585/),month,20.3,227380,DB02010,Staurosporine
,9698244,half-life,"Following initial adsorption, pharmacokinetic studies demonstrated that Stsp had a half-life of 51.6 min in plasma and 75.3 min in RBC.",High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698244/),min,51.6,241764,DB02010,Staurosporine
,9698244,half-life,"Following initial adsorption, pharmacokinetic studies demonstrated that Stsp had a half-life of 51.6 min in plasma and 75.3 min in RBC.",High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698244/),min,75.3,241765,DB02010,Staurosporine
,9698244,Stsp,"Thus, plasma Stsp was in the cancer therapy range of 1-10 ng/ml for 2.7 h following a bolus injection.",High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698244/),[ng] / [ml],1-10,241766,DB02010,Staurosporine
,11186240,elimination half-life,"After that, UCN-01 was eliminated bi-exponentially with an elimination half-life of 5.14+/-1.12 to 8.32+/-1.80 h.",The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11186240/),h,5.14,247534,DB02010,Staurosporine
,11186240,elimination half-life,"After that, UCN-01 was eliminated bi-exponentially with an elimination half-life of 5.14+/-1.12 to 8.32+/-1.80 h.",The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11186240/),h,8.32,247535,DB02010,Staurosporine
,11186240,total clearance (CLtotal),The total clearance (CLtotal) ranged from 0.383 to 0.666+/-0.149 L h(-1) kg(-1).,The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11186240/),[l] / [h·kg],0.383,247536,DB02010,Staurosporine
,11186240,total clearance (CLtotal),The total clearance (CLtotal) ranged from 0.383 to 0.666+/-0.149 L h(-1) kg(-1).,The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11186240/),[l] / [h·kg],0.,247537,DB02010,Staurosporine
,10555120,Maximal concentrations,"Maximal concentrations of 73 ng/ml, 1.9 ng/ml and 126 ng/ml for CGP 41 251 (I), III and V were found, respectively.",Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10555120/),[ng] / [ml],73,259185,DB02010,Staurosporine
,10555120,Maximal concentrations,"Maximal concentrations of 73 ng/ml, 1.9 ng/ml and 126 ng/ml for CGP 41 251 (I), III and V were found, respectively.",Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10555120/),[ng] / [ml],1.9,259186,DB02010,Staurosporine
,10555120,Maximal concentrations,"Maximal concentrations of 73 ng/ml, 1.9 ng/ml and 126 ng/ml for CGP 41 251 (I), III and V were found, respectively.",Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10555120/),[ng] / [ml],126,259187,DB02010,Staurosporine
,10367744,elimination half-lives,"The elimination half-lives in mice, rats and dogs were 3.00-3.98, 4.02-4.46 and 11.6 h, respectively.","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),h,3.00-3.98,260828,DB02010,Staurosporine
,10367744,elimination half-lives,"The elimination half-lives in mice, rats and dogs were 3.00-3.98, 4.02-4.46 and 11.6 h, respectively.","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),h,4.02-4.46,260829,DB02010,Staurosporine
,10367744,elimination half-lives,"The elimination half-lives in mice, rats and dogs were 3.00-3.98, 4.02-4.46 and 11.6 h, respectively.","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),h,11.6,260830,DB02010,Staurosporine
,10367744,total clearance (Cl(total)),"The total clearance (Cl(total)) values in mice, rats and dogs were high (1.93-2.64, 2.82-3.86 and 0.616 l/h per kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [h·kg],1.93-2.64,260831,DB02010,Staurosporine
,10367744,total clearance (Cl(total)),"The total clearance (Cl(total)) values in mice, rats and dogs were high (1.93-2.64, 2.82-3.86 and 0.616 l/h per kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [h·kg],2.82-3.86,260832,DB02010,Staurosporine
,10367744,total clearance (Cl(total)),"The total clearance (Cl(total)) values in mice, rats and dogs were high (1.93-2.64, 2.82-3.86 and 0.616 l/h per kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [h·kg],0.616,260833,DB02010,Staurosporine
,10367744,volumes of distribution at steady-state,"The volumes of distribution at steady-state in mice, rats and dogs were large (7.89-8.42, 13.0-16.9 and 6.09 l/kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [kg],7.89-8.42,260834,DB02010,Staurosporine
,10367744,volumes of distribution at steady-state,"The volumes of distribution at steady-state in mice, rats and dogs were large (7.89-8.42, 13.0-16.9 and 6.09 l/kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [kg],13.0-16.9,260835,DB02010,Staurosporine
,10367744,volumes of distribution at steady-state,"The volumes of distribution at steady-state in mice, rats and dogs were large (7.89-8.42, 13.0-16.9 and 6.09 l/kg, respectively).","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),[l] / [kg],6.09,260836,DB02010,Staurosporine
,10367744,ratio of tumor to plasma concentrations,"UCN-01 concentrations in tumor tissue were much higher than those in the plasma, and the ratio of tumor to plasma concentrations was about 500 at 24 h after five consecutive doses.","Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367744/),,500,260837,DB02010,Staurosporine
